View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Special Focus
  2. Covid-19
April 24, 2020

Covid-19: Healthcare daily update – cardiac injury can occur in those with no previous risk – BCG vaccination may offer heterologous immunity

By Paul Dennis

24 April

Treatment of cardiovascular disease during the Covid-19 pandemic
New research has shown that although those with CVD are at risk, cardiac injury can occur in those with confirmed Covid-19 and no previous cardiovascular (CV) risk. This will increase the use of and the demand for various CV treatments as patients are treated symptomatically and potentially longer-term if the myocardium effects are long-lasting.

BCG vaccination may induce heterologous immunity and protect against Covid-19
Preliminary reports from epidemiological studies suggest that countries with universal BCG vaccination programs have been impacted less by Covid-19, leading researchers to theorise that BCG vaccination may offer some level of heterologous immunity against Covid-19.

The impact of big pharma on Covid-19
Pharmaceutical companies taking centre stage in the Covid-19 fight, such as Gilead and Eli Lilly, are seeing positive growth on the stock market and a new burst of innovation in the infectious disease landscape as the race for treatment approval for a Covid-19 therapy takes off. But what impact are pharmaceutical companies having in a time of strong clinical need?

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU